Key Perspectives: Cilta-Cel in Multiple Myeloma

Long-term follow-up from CARTITUDE-1 is prompting a shift in clinical practice, including earlier consideration of chimeric antigen receptor T-cell therapy. The trial has influenced regulatory agencies to accept minimal residual disease as a surrogate for survival in new studies.

As new therapies like bispecifics and trispecific antibodies emerge, clinicians must tailor treatment sequencing. Yet, cilta-cel remains a cornerstone therapy, especially for younger, fit patients or those with high-risk features who may benefit most from its curative potential.

Ultimately, these findings challenge the long-standing notion that multiple myeloma is incurable, offering new hope and optimism to patients and clinicians alike.